Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1α production and mRNA expression

Cytokine

Volumn 18, Issue 1, 2002, Pages 35-42

  Pozo, David ^a   Guerrero, Juan M ^a   Calvo, Juan R ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

CC chemokines; Immunomodualtion; Inflammation; Macrophage; PACAP; VIP

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; PROTEIN KINASE C INHIBITOR; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; ADCYAP1 PROTEIN, MOUSE; CHEMOKINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1; NEUROPEPTIDE; PROTEIN KINASE C;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE EXPRESSION; INHIBITION KINETICS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL LINE; DOSE RESPONSE; METABOLISM; TIME;

ANIMALS; CELL LINE; CELLS, CULTURED; CHEMOKINES; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; LIPOPOLYSACCHARIDES; MACROPHAGE INFLAMMATORY PROTEIN-1; MICE; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN KINASE C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0036020270     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2002.1024     Document Type: Article

References (48)

1. The role of the macrophage in immune regulation
2. Macrophages and inflammatory mediators
3. Chemokines-chemotactic cytokines that mediate inflammation
4. The biology of chemokine and their receptors
5. The role of MIP-1α in inflammation and haematopoiesis
6. Prognostic value of MIP-1 alpha, TGF-β2, sELAM-1, and sVCAM-1 in patients with gram-positive sepsis
7. Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF-MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo
8. Macrophage inflammatory protein-1 alpha expression in interstitial lung disease
9. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs
10. Immunobiology of vasoactive intestinal peptide (VIP)
11. Anti-inflammatory actions of VIP/PACAP. Role in endotoxemia
12. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: Role in lethal endotoxic shock
13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages
14. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFN gamma synthesis by T cells
15. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: In vitro and in vivo studies
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation
17. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide enhance IL-10 production by murine macrophages: In vitro and in vivo studies
18. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6
19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating factor-kB and cAMP response element-binding protein/c-Jun
20. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappa B and Ets activation
21. Inhibition of IFN-γ-induced Janus kinase-1-STAT1 activation in macrophages by vaso-active intestinal peptide and pituitary adenylate cyclase-activating polypeptide
22. Demonstration of immunoreactivity vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus
23. Expression of vasoactive intestinal peptide in lymphocytes: A possible endogenous role in the regulation of the immune system
24. Regulation of VIP production and secretion by murine lymphocytes
25. International Union of Pharmacology. XVII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide
26. PACAP, PACAP receptors and intracellular signalling
27. Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems
28. Multiple receptors for PACAP and VIP
29. Development of high affinity selective VIP1 receptor agonist
30. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor
31. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes
32. In vitro properties of high affinity selective antagonist of the VIP1 receptor
33. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors
34. Early responses to infection: Chemokines as mediators of inflammation
35. Chemokines and disease
36. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators
37. VIP as a modulator of lung inflammation and airway constriction
38. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor-α production in injured spinal cord and in activated microglia via a cAMP-dependent pathway
39. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages
40. Homologous regulation of vasoactive intestinal peptide (VIP) receptors on rat peritoneal macrophages
41. Neuropeptide regulation of cytokine expression: Effects of VIP and Ro 25-1553
42. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo
43. IL-4 regulates VIP receptor subtype 2 mRNA (VPAC2) expression in T cells in murine schistosomiasis
44. Exogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism
45. C/EBP, NF-κB, and c-Ets family members and transcriptional regulation of the cell-specific and inducible macrophage inflammatory protein 1 alpha immediate-early gene
46. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression
47. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
48. Induction of the chemokine beta peptides, MIP-1α and MIP-1β, by lipopolysaccharide is differentially regulated by immunomodulatory cytokines gamma-IFN, IL-10, IL-4, and TGF-β